Vaccinex, Inc. Announces Preliminary Data from the SIGNAL Clinical Trial (Investigational Drug VX15/2503 as a Potential Treatment for Huntington’s Disease)
April 24, 2017 10:28 ET
|
Vaccinex, Inc.
- Subjects were rapidly recruited and consistently retained and dosed - - No concerning safety signals were identified - – Imaging data from SIGNAL Cohort A indicate treatment effect on...
Vaccinex, Inc. Receives Orphan Drug Designation from U.S. FDA for its Lead Antibody Product Candidate, VX15, as a Potential Treatment for Huntington’s Disease
August 23, 2016 10:15 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Aug. 23, 2016 (GLOBE NEWSWIRE) -- Vaccinex, Inc., a clinical-stage biotechnology company engaged in the discovery and development of therapeutic monoclonal antibodies to treat...
Vaccinex Announces the Publication of Data Demonstrating Preclinical Efficacy in an Animal Model of Huntington Disease
February 17, 2015 11:05 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Feb. 17, 2015 (GLOBE NEWSWIRE) -- Vaccinex, Inc., a clinical-stage immunotherapy company engaged in the discovery and development of therapeutic monoclonal antibodies, today announced...